Posted on

cbd celiac

According to studies, Celiac disease can lead to nerve damage 9 . CBD can be a solution for neuropathy pain 10 , as it has neuroprotective 11 and neurodegenerative 12 properties. Taking CBD oil, can therefore, help repair this damage for better nerve function.

CBD triggers the production of CB1 and CB2, boosting the body’s immune system. It can also help relieve celiac disease symptoms such as pain, inflammation, loss of appetite, and irritation that affect the gastrointestinal tract.

How To Use CBD To Treat Celiac Disease

Nonetheless, more studies should be done to explore the therapeutic effects of CBD towards easing the symptoms of Celiac disease.

You can also use CBD Vape pens for vaping the oil, thus making absorption quick and the relief of symptoms faster. If vaping or sublingual use is problematic, you can use CBD capsules because they are easier to ingest.

Why CBD Can Be An Effective Treatment For Celiac Disease

CBD is extracted alongside THC from cannabis yet their effects on the human body are worlds apart. CBD is recognized around the world 1 for its health benefits due to its anti-inflammatory properties 2 and ability to alleviate pain 3 As a result, it could be considered an effective treatment for health conditions like celiac disease. Celiac disease is an autoimmune condition that makes the intestinal wall reactive to gluten 4 .

CD is a chronic, inflammatory, small intestinal disorder that can lead to severe villous atrophy, malab-sorption, and malignancy. Susceptibility to CD, its activation, and the ensuing inflammatory cascade involve a combination of environmental and genetic factors that trigger immunologic mechanisms. 11 CD is the only autoimmune disease with a known trigger, which is the ingestion of the gluten proteins found in wheat, barley, and rye. All patients must express the antigen-presenting molecules human leukocyte antigen (HLA)-DQ2 and/or HLA-DQ8, the presence of which is the single most important predisposing genetic factor for CD. 12 HLA-DQ2 and HLA-DQ8 then bind gluten peptides that have undergone deamidation by transglutamin-ase 2 (TG2), an enzyme tissue transglutaminase; this deamidation increases the gluten peptides’ affinity for HLA-DQ2 and HLA-DQ8 and results in a more destructive intestinal CD4 + T-cell response. 13 Once activated, gluten-reactive CD4 + T cells produce cytokines and induce an inflammatory cascade that results in intestinal inflammation—characterized by villous atrophy, crypt hyperplasia, and infiltration of inflammatory cells—which leads to malabsorption. 12 Based on this mechanism of action, the current standard treatment of choice is strict, lifelong adherence to a gluten-free diet that eliminates wheat, rye, and barley.

Novel Therapies

In order to create an effective peptide-based therapy for CD, an important step is the identification of the gluten peptides that trigger intestinal T-cell responses when patients with CD consume wheat, rye, or barley. Recently, researchers from the Australian company Nexpep analyzed the gluten protein and broke it down into about 2,700 distinct fragments. These fragments were then added to the blood of 200 CD patients, and the immune responses to the fragments were compared to the responses seen after the same patients consumed wheat bread, rye muffins, and boiled barley. Three peptides—gliadin, hordein, and secalin—were found to trigger a heightened immune response. 27

Probiotics with Enzymes

CD is more common than was previously thought, and recent studies have shown a much higher global prevalence rate. 3 In the past, CD was considered to be a rare disorder in North America, mostly affecting individuals of northern European descent, and the disease was usually diagnosed in childhood. At that time, diagnosis was made in patients with typical gastrointestinal symptoms and classic symptoms of malabsorption, with confirmation by small intestinal biopsy. 5 The discovery of highly sensitive and specific serologic markers—including antigliadin, antiendomysium, and antitransglutaminase antibodies— has allowed clinicians to evaluate the true prevalence of CD and identify patients with clinically mild, atypical, or even silent forms of CD. 6